Results 81 to 90 of about 1,970,330 (303)

Immunization with detoxified TNFα elicits neutralizing antibodies and ameliorates inflammatory shock and autoimmune arthritis in mice

Frontiers in Immunology
IntroductionTumor necrosis factor-⍺ (TNF⍺) is central to the pathogenesis of autoimmune and inflammatory diseases, and monoclonal antibody-based TNF⍺ inhibitors are amongst the most used biologics worldwide.
Wen-Ling Hsu, He Ren, Wei-Chiao Huang, Ramkumar T. Annamalai, Yumiao Zhang, Jonathan F. Lovell   +5 more
doaj   +1 more source

Myogenic Fusogen‐Engineered Lipid Nanoparticles Enhance mRNA Delivery in Skeletal Muscle

Advanced Functional Materials, EarlyView.
This study reports a biomimetic strategy of engineering full‐length Myomaker, a muscle‐specific fusogen, into lipid nanoparticles (LNPs) to harness the native myoblast fusion capability for skeletal muscle mRNA delivery. The resulting Mymk‐LNPs enhance transfection in differentiating myocytes and enable Cre‐mediated reporter activation in injured ...
Fangyu Zhang, Zhisheng Xu, Yaou Duan, Yehui Sun, Shiying Wu, Tao Long, Mateusz Durbacz, Li Zhang, Yufen Xiao, Yu‐Chung Pien, Erick D. Guerrero, Zeru Tian, Xu Wang, Pratima Basak, Sumanta Chatterjee, Ning Liu, Xiaochun Li, Eric N. Olson, Daniel J. Siegwart   +18 more
wiley   +1 more source

Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study

Frontiers in Immunology
BackgroundBVAC-C, a B cell– and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7, was well tolerated in HPV–positive recurrent cervical carcinoma patients in a phase I study.
Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Eun-Suk Kang, Duck Cho, Yong-Man Kim, Kidong Kim, Jae-Weon Kim, Hee Seung Kim, Young-Tae Kim, Jung-Yun Lee, Myong Cheol Lim, Taegwon Oh, Boyeong Song, Insu Jeon, Myunghwan Park, Wu Hyun Kim, Chang-Yuil Kang, Byoung-Gie Kim   +18 more
doaj   +1 more source

Trypsin digest of cancer cells surface stimulates anti-tumor immune response better than cancer cells themselves [PDF]

, 2010
Antigens expressed on the surface of cancer cells are accessible targets for both humoral and cell-mediated immune responses, and are therefore potential candidates for vaccine development.
Balashova Elena, Petr Lokhov
core   +1 more source

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

Advanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal, Younan Ma, Asad Khanmohammed, Dipen Parande, Hanming Zhang, Saket Dolare, Juliet Chen, Apiwat Wangweerawong, Saswata Karmakar, Hongfeng Deng, Frank Koppenhagen, Shraddha Sharma, Eric Reyes, Sherry He, Lianne Boeglin, Caroline Woo, Azadeh Paksa, Ayed Allawzi, Anusha Dias, Gregory Troiano, Shrirang Karve, Frank DeRosa   +21 more
wiley   +1 more source

Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes

Vaccines, 2015
Tumor vaccine design requires prediction and validation of immunogenic MHC class I epitopes expressed by target cells as well as MHC class II epitopes expressed by antigen-presenting cells essential for the induction of optimal immune responses.
Peng Peng Ip, Hans W. Nijman, Toos Daemen   +2 more
doaj   +1 more source

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

, 2012
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS ...
안상훈
core  

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. [PDF]

, 2009
Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003, result in high morbidity and mortality.
Sutter, G. (Gerd), Sutter Gerd, Rimmelzwaan, Guus F., Osterhaus, A.D.M.E. (Albert), Yasemin Suezer, Gerrie de Mutsert, Suezer, Yasemin, Geert van Amerongen, Löwer, Johannes, Fouchier Ron A. M., Osterhaus, Albert D. M. E., Kreijtz, Joost H. C. M., Mutsert, Gerrie de, Fouchier, Ron A. M., Fouchier, R.A.M. (Ron), Guus F Rimmelzwaan, van den Brand Judith M. A., Löwer Johannes, Johannes Löwer, Kreijtz, J.H.C.M. (Joost), Suezer, Y., Judith M A van den Brand, Suezer Yasemin, Mutsert, G. (Gerrie) de, Amerongen, G. (Geert) van, Rimmelzwaan Guus F., Brand, J.M.A. (Judith) van den, Joost H C M Kreijtz, Sutter, Gerd, Schwantes, Astrid, de Mutsert Gerrie, Brand, Judith M. A. van den, Osterhaus Albert D. M. E., Schwantes Astrid, Scwantes, A. (Astrid), Ron A M Fouchier, van Amerongen Geert, Albert D M E Osterhaus, Gerd Sutter, Astrid Schwantes, Rimmelzwaan, G.F. (Guus), Kreijtz Joost H. C. M., Amerongen, Geert van, Löwer, J., Fouchier, Ron A.M.; id_orcid, Scwantes, Astrid, van Amerongen, Geert, van den Brand, Judith M.A., Osterhaus, Albert D.M.E., Kreijtz, Joost H.C.M., de Mutsert, Gerrie   +50 more
core   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: Potential clinical impact

, 2015
[[abstract]]The goal of therapeutic HPV vaccines is the induction of cytotoxic T lymphocyte immunity against HPV-associated cancers. Recombinant proteins and synthetic peptides have high safety profiles but low immunogenicity, which limits their efficacy
Shen, KY;Chang, LS;Leng, CH;Liu, SJ
core   +1 more source